Name of the Procedure:

Injection, Carfilzomib, 1 mg (J9047)

• Common Name(s): Carfilzomib Injection
• Technical/Medical Term: Carfilzomib therapy

Summary

Carfilzomib injection is a medical procedure where a drug named Carfilzomib is administered intravenously. It's used primarily in the treatment of multiple myeloma, a type of blood cancer.

Purpose

Carfilzomib therapy addresses multiple myeloma:

• Goals/Expected Outcomes: To reduce the number of cancer cells, alleviate symptoms, and improve the patient's quality of life. It aims to manage the disease progression and prolong survival.

Indications

• Specific Symptoms/Conditions: Indicated for patients with relapsed or refractory multiple myeloma.
• Patient Criteria: Typically suitable for adults who have received one or more previous therapies.

Preparation

• Pre-Procedure Instructions:
  • Ensure adequate hydration before the infusion.
  • Premedication with dexamethasone may be required to prevent infusion reactions.
  • Specific adjustments in medication may be advised by the healthcare provider.
• Diagnostic Tests/Assessments: Baseline blood tests to evaluate kidney and liver function, and complete blood count.

Procedure Description

• Step-by-step Explanation:
  1. The patient is seated comfortably and prepared for an intravenous (IV) line.
  2. Carfilzomib is diluted and prepared according to specific protocols.
  3. The drug is administered as an IV infusion over a specified period, often taking about 30 minutes.
  4. Monitoring for any adverse reactions during and post-infusion.
• Tools/Equipment: IV setup, Carfilzomib solution, infusion pump.
• Anesthesia/Sedation: Not typically required, but premedication for an infusion reaction may be given.

Duration

Approximately 30 minutes for the infusion itself. Additional time may be needed for preparation and post-infusion observation.

Setting

Usually performed in a hospital outpatient clinic, infusion center, or specialized cancer treatment center.

Personnel

• Healthcare Professionals Involved: Oncologists/hematologists, infusion nurses, and possibly pharmacists.

Risks and Complications

• Common Risks: Fatigue, low blood counts, nausea, fever.
• Rare Risks: Heart failure, lung complications, severe infusion reactions.

Benefits

• Expected Benefits: Reduction in cancer cell count, symptom relief, improvement in overall health and longevity.
• Realization Time: Benefits can be noticed over a series of treatment cycles.

Recovery

• Post-Procedure Care: Regular monitoring of blood counts and organ function.
• Recovery Time: Varies but often includes a rest period after infusion. Patients may resume normal activities based on their physical condition and response.
• Follow-Up: Scheduled cycles of Carfilzomib, and frequent health evaluations.

Alternatives

• Other Treatment Options: Other chemotherapies, stem cell transplant, radiation, and targeted therapies.
• Pros and Cons: Alternative therapies might have different side effect profiles, effectiveness, and costs. The choice depends on the patient's specific medical condition and treatment history.

Patient Experience

• During the Procedure: May feel mild discomfort at IV site, possible mild infusion reaction symptoms (fever, chills).
• After the Procedure: Possible fatigue, need for hydration, and rest. Pain management includes standard analgesics if necessary. Regular communication with healthcare providers for any arising symptoms or concerns.